A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Phytogenic
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms
  • Paclitaxel
  • Peritoneal Neoplasms
  • Polyglutamic Acid

abstract

  • PPX at 175 mg/m(2) every 21 days has a modest activity of limited duration when given as second or third line therapy in patients with epithelial ovarian or primary peritoneal cancer. The incidence of neuropathy using this dose in recurrent ovarian cancer is higher than predicted from studies in other tumors with PPX. The Gynecology Oncology Group (GOG) is currently exploring its use at 135 mg/m(2) every 28 days in a randomized trial evaluating maintenance chemotherapy in first remission.

publication date

  • December 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2008.07.049

PubMed ID

  • 18829087

Additional Document Info

start page

  • 455

end page

  • 60

volume

  • 111

number

  • 3